PPRT 321

Drug Profile

PPRT 321

Alternative Names: Saw palmetto - PharmaPrint; Serenoa repens - PharmaPrint

Latest Information Update: 20 Feb 2008

Price : $50

At a glance

  • Originator PharmaPrint
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 02 Oct 2001 No-Development-Reported for Benign prostatic hyperplasia in USA (Unknown route)
  • 23 Mar 1999 Data have been added to the therapeutic trials and adverse events sections
  • 14 May 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top